These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37554894)

  • 1. Serum lipoprotein(a), and plasminogen activator inhibitor-1 in uncomplicated type 2 diabetes mellitus: a case-control study.
    Abdullah FE; Ahmed SN
    Ann Med Surg (Lond); 2023 Aug; 85(8):3801-3805. PubMed ID: 37554894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibronectin and lipoprotein(a) are inversely related to plasminogen activator inhibitor type-1 levels in Type 2 diabetic patients without complications.
    Testa R; Bonfigli AR; Sirolla C; De Grazia G; Compagnucci P; Manfrini S; Fumelli D; Testa I
    Diabetes Nutr Metab; 2000 Oct; 13(5):269-75. PubMed ID: 11105969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein(a), tissue plasminogen activator and plasminogen activator inhibitor 1 levels in hyperlipidaemic patients in Kuwait.
    Akanji AO; Abdullah A; Tahzeeb S
    Eur J Clin Invest; 1997 May; 27(5):380-6. PubMed ID: 9179544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus.
    Testa R; Bonfigli AR; Piantanelli L; Manfrini S; Testa I; Gregorio F
    Diabetes Res Clin Pract; 1996 Jul; 33(2):111-8. PubMed ID: 8879966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of obesity on fibrinolytic activity and plasma lipoprotein (a) levels in patients with type 2 diabetes mellitus in Korea.
    Park YS; Park S; Park KS; Kim SY; Lee HK; Koh CS; Min HK; Kim JQ
    Diabetes Res Clin Pract; 1994 May; 24(1):25-31. PubMed ID: 7924883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
    Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A significant relationship between plasminogen activator inhibitor type-1 and lipoprotein(a) in non-insulin-dependent diabetes mellitus without complications.
    Testa R; Bonfigli AR; Pieri C; Marra M; Sirolla C; Manfrini S; Testa I
    Int J Clin Lab Res; 1998; 28(3):187-91. PubMed ID: 9801931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina.
    Daví G; Violi F; Catalano I; Giammarresi C; Putignano E; Nicolosi G; Barbagallo M; Notarbartolo A
    Blood Coagul Fibrinolysis; 1991 Feb; 2(1):41-5. PubMed ID: 1772997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between lipoprotein(a) phenotypes and plaminogen activator inhibitor type 1 in diabetic patients.
    Hernández C; Chacón P; García-Pascual L; Mesa J; Simó R
    Thromb Res; 2000 Jul; 99(2):119-27. PubMed ID: 10946085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do plasminogen activator inhibitor (PAI-1) or tissue plasminogen activator PAI-1 complexes predict complications in Type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study.
    Bosnyak Z; Forrest KY; Maser RE; Becker D; Orchard TJ;
    Diabet Med; 2003 Feb; 20(2):147-51. PubMed ID: 12581266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.
    Al-Hamodi Z; Ismail IS; Saif-Ali R; Ahmed KA; Muniandy S
    Cardiovasc Diabetol; 2011 Mar; 10():23. PubMed ID: 21414238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral artery disease in type 2 diabetes: the role of fibrinolysis.
    Lapolla A; Piarulli F; Sartore G; Rossetti C; Martano L; Carraro P; De Paoli M; Fedele D
    Thromb Haemost; 2003 Jan; 89(1):91-6. PubMed ID: 12540958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A strong inverse relationship between PAI-1 and Lp(a) in hypertensive Type 2 diabetic patients.
    Testa R; Bonfigli AR; Sirolla C; Pieri C; Marra M; Antonicelli R; Manfrini S; Compagnucci P; Testa I
    Diabetes Nutr Metab; 1999 Dec; 12(6):400-6. PubMed ID: 10782561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein (a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes.
    Buechler C; Ullrich H; Ritter M; Porsch-Oezcueruemez M; Lackner KJ; Barlage S; Friedrich SO; Kostner GM; Schmitz G
    Blood; 2001 Feb; 97(4):981-6. PubMed ID: 11159526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycation amplifies lipoprotein(a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells.
    Zhang J; Ren S; Shen GX
    Atherosclerosis; 2000 Jun; 150(2):299-308. PubMed ID: 10856522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis.
    Segarra A; Chacón P; Martinez-Eyarre C; Argelaguer X; Vila J; Ruiz P; Fort J; Bartolomé J; Camps J; Moliner E; Pelegrí A; Marco F; Olmos A; Piera L
    J Am Soc Nephrol; 2001 Jun; 12(6):1255-1263. PubMed ID: 11373350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinolytic parameters, lipid status and lipoprotein(a) in ischemic stroke patients.
    Vucković BA; Djerić MJ; Ilić TA; Canak VB; Kojić-Damjanov SLj; Zarkov MG; Cabarkapa VS
    Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():12-7. PubMed ID: 20229676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of niceritrol on fibrinolysis and lipoprotein (a) levels in patients with coronary artery disease.
    Suefuji H; Ogawa H; Yasue H; Imoto N; Sakamoto T; Miyao Y; Kaikita K; Soejima H; Nishiyama K
    Coron Artery Dis; 1996 Feb; 7(2):167-72. PubMed ID: 8813450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between serum and tear levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in diabetic retinopathy.
    Jasmiad NB; Abd Ghani RB; Agarwal R; Ismail ZB; Mohd Abdullah AA; Idorus MY
    BMC Ophthalmol; 2022 Sep; 22(1):357. PubMed ID: 36057550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus.
    Morishita E; Asakura H; Jokaji H; Saito M; Uotani C; Kumabashiri I; Yamazaki M; Aoshima K; Hashimoto T; Matsuda T
    Atherosclerosis; 1996 Feb; 120(1-2):7-14. PubMed ID: 8645373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.